Evidence map›Paper›PMID 34730399›Full record

ArticleJournal of virology2022

Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.

Mousumi Khatun, Krishna Kumar, Ayana Baidya, Rajiv Kumar Mondal, Ondřej Baszczyňski, Filip Kalčic, Soma Banerjee, Gopal Krishna Dhali, Kausik Das, Abhijit Chowdhury and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Mousumi Khatun *Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Krishna Kumar *Structural Biology and Bioinformatics Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Ayana Baidya *Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Rajiv Kumar MondalCentre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Ondřej BaszczyňskiInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Filip KalčicInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Soma BanerjeeCentre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Gopal Krishna DhaliDepartment of Gastroenterology, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Kausik DasDepartment of Hepatology, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Abhijit ChowdhuryDepartment of Hepatology, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Zlatko JanebaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Saikat ChakrabartiStructural Biology and Bioinformatics Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Simanti DattaCentre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Institute of Post Graduate Medical Education and Research · INCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZIndian Institute of Chemical Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleos(t)ide analogues entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are recommended as first-line monotherapies for chronic hepatitis B (CHB). Multiple HBV genotypes/subgenotypes have been described, but their impact on treatment response remains largely elusive. We investigated the effectiveness of ETV/TDF on HBV/D-subgenotypes, D1/D2/D3/D5, studied the structural/functional differences in subgenotype-specific reverse transcriptase (RT) domains of viral polymerase, and identified novel molecules with robust inhibitory activity on various D-subgenotypes. Transfection of Huh7 cells with full-length D1/D2/D3/D5 and

Indexed as

Drug DesignAntiviral AgentsDrug Resistance, ViralGenotypeGuanineHepatitis B, ChronicHepatitis B virusHumansMutationOrganophosphonatesProdrugsProtein DomainsReverse Transcriptase InhibitorsRNA-Directed DNA PolymeraseTenofovirViral LoadAntiviral AgentsentecavirGuanineOrganophosphonatesProdrugsReverse Transcriptase InhibitorsRNA-Directed DNA PolymeraseTenofovirantiviral activityentecavirhepatitis B virus D-subgenotypeshigh throughput virtual screeningphosphonate prodrugtenofovir

Identifiers

PMID34730399
PMCPMC8791253
OpenAlexW3210482613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.